linjc16/ctgov huggingface dataset:
Regeneration of Bronchial Epithelium During Chronic Obstructive Pulmonary Disease

Study Overview
=================
Brief Summary
-----------------
Airway epithelium integrity is essential to maintain its role of mechanical and functional barrier. Recurrent epithelial injuries require a complex mechanism of repair to restore its integrity. In chronic obstructive pulmonary disease (COPD), an abnormal airway epithelial repair may participate in airway remodelling. The objective was to determine if airway epithelial wound repair of airway epithelium is abnormal in COPD.

Detailed Description
-----------------
Patients scheduled for lung resection were prospectively recruited. Demographic, clinical data and pulmonary function tests results were recorded. Emphysema was visually scored and histological remodelling features were noted. Primary bronchial epithelial cells (BEC) were extracted and cultured for wound closure assay. The investigators determined the mean speed of wound closure (MSWC) and cell proliferation index, matrix metalloprotease (MMP)-2, MMP-9 and cytokines levels in supernatants of BEC 18 hours after cell wounding. In a subset of patients, bronchiolar epithelial cells were also cultured for wound closure assay for MSWC analyze.

Official Title
-----------------
Regeneration of Bronchial Epithelium During Chronic Obstructive Pulmonary Disease

Conditions
-----------------
COPD

Intervention / Treatment
-----------------
* Other: bronchial epithelial cell culture


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 6 Patients scheduled for lung resection for cancer Exclusion Criteria: Patients with asthma, cystic fibrosis, bronchiectasis or pulmonary fibrosis were excluded

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with COPD<br>patients with COPD | Other: bronchial epithelial cell culture<br> <br> |
| patients without COPD<br>patients without COPD | Other: bronchial epithelial cell culture<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean speed of wound closure (MSWC) of wounded bronchial epithelial cell culture obtained from COPD and control patients |  | hour 18 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cell proliferation index in supernatants of bronchial epithelial cells 18 hours after cell wounding. |  | hour 18 | 
| Matrix metalloprotease (MMP)-2 level in supernatants of bronchial epithelial cells 18 hours after cell wounding. |  | hour 18 | 
| Matrix metalloprotease (MMP)-9 level in supernatants of bronchial epithelial cells 18 hours after cell wounding. |  | hour 18 | 
| Cytokines levels in supernatants of bronchial epithelial cells 18 hours after cell wounding. |  | hour 18 |
Rapid Clamp Release Post Trans-radial Cardiac Catheterization

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to compare different short durations of radial clamp application following an angiogram via a trans-radial approach.

Detailed Description
-----------------
This is a single-center, prospective, randomized study that will enroll patients that are referred for an angiogram and will compare 3 different durations of radial clamp applications. Patients will be randomly assigned to either 10, 20 or 30-minute clamp applications. The clamps will be gradually released at the end of the assigned durations and participants will be assessed for the radial artery occlusion, hematoma, and other bleeding events.

Official Title
-----------------
Reducing Compression Duration Post Trans Radial Cardiac Catheterization

Conditions
-----------------
Cardiac Catheterization

Intervention / Treatment
-----------------
* Other: Compression clamp release


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnostic catheterization 5 F slender sheath Normal ulno-palmar circulation Exclusion Criteria: Abnormal ulno-palmar circulation type D Ad hoc percutaneous coronary intervention Heparin or other anticoagulation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 10 minutes<br>Compression clamp release start after 10 minutes | Other: Compression clamp release<br>* Standard compression clamp is used and will be released at different times according to randomization<br>|
| Experimental: 20 minutes<br>Compression clamp release start after 20 minutes | Other: Compression clamp release<br>* Standard compression clamp is used and will be released at different times according to randomization<br>|
| Active Comparator: 30 minutes<br>Compression clamp release start after 30 minutes | Other: Compression clamp release<br>* Standard compression clamp is used and will be released at different times according to randomization<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hematoma | Hematoma larger than 5 cm | 1 hour | 
| Radial artery occlusion | Assessed by Doppler | 1 hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Bleeding - any | Minor hematoma | 1 hour |
Cognitive and Behavioral Outcomes of School-aged Children Who Were Born Preterm

Study Overview
=================
Brief Summary
-----------------
This study evaluates the cognitive and behavioral outcomes including image findings of school-aged children who were born preterm compared with who were born term gestational age.

Detailed Description
-----------------
There are lots of studies published that school-aged children who were born preterm has some behavioral problems in school and they also have poor academical achievement.

Official Title
-----------------
Cognitive and Behavioral Outcomes of School-aged Children Who Were Born Preterm

Conditions
-----------------
Very Low Birth Weight Infants

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children former preterm infants < 32 weeks of gestation or 1,500gm of birth weight children former normal term infants Exclusion Criteria: major congenital anomaly neuromuscular disease chromosomal anomaly

Ages Eligible for Study
-----------------
Minimum Age: 8 Years
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Preterm cohort<br>Among the infants who were born and admitted to Seoul National University Hospital from 2008 to 2009, the birth weight of the infants less than 1,500g or gestational age less than 32 weeks patients were enrolled. | |
| Term control cohort<br>The infants who were born from 2008 to 2009 with term gestational age will be enrolled. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cognitive function test |  | 8 Years old | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Brain MRI |  | 8 Years old | 
| Korean Child Behavior Checklist |  | 8 Years old | 
| Korean ADHD Rating Scale-IV |  | 8 Years old | 
| Wechsler Scale of Intelligence-IV |  | 8 Years old | 
| Advanced Test of Attention |  | 8 Years old | 
| Children's color trails test |  | 8 Years old | 
| STROOP |  | 8 Years old | 
| Wisconsin Card Sorting Test |  | 8 Years old |
A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy

Study Overview
=================
Brief Summary
-----------------
This study has patients responding to two sets of surveys that will tell their doctor or nurse about their readiness to begin self-injection. In addition, patients will have their self-injection observed and evaluated on up to three visits

Official Title
-----------------
A Multicenter, Open-Label, Two-Arm Prospective Study to Evaluate the Impact of Patient Readiness to Self-Inject on Outcomes When Using the Copaxone® Prefilled Syringes [The READY Trial]

Conditions
-----------------
Multiple Sclerosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or Female, 18 years of age or older, with diagnosis of RRMS Naive to treatment or previously treated with an IFN. Exclusion Criteria: Not eligible for treatment based on clinical criteria and current indication. Unable to respond to surveys or provide informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence of self-injection assessed by self-report at each follow-up visit |  | 12 months |
Inspiratory Muscle Training for Patients With Chronic Obstructive Pulmonary Disorder

Study Overview
=================
Brief Summary
-----------------
This study is a randomized controlled trial with the aim of evaluating the effect of homebased inspiratory muscle training (IMT) for patients with COPD in Norway. The intervention group will train with threshold IMT for 6 weeks. The control group will not participate in any other training method or sham. Evaluation parameters are maximal inspiratory pressure, six minute walk test, COPD assessment test, modified Medical research council dyspnea scale and spirometry.

Conditions
-----------------
Pulmonary Disease, Chronic Obstructive

Intervention / Treatment
-----------------
* Device: Threshold IMT Philips Respironics


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: COPD grade III-IV, Inhabitant of Hedmark (Løten, Våler, Åsnes, Hamar, Elverum) Exclusion Criteria: Undergoing exercise based physical therapy treatment, not able to do IMT physically or mentally
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br>No treatment other than medical | |
| Experimental: Intervention<br>Inspiratory muscle training | Device: Threshold IMT Philips Respironics<br>* Inspiratory muscle training<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximal inspiratory pressure |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Six minute walk test |  | 6 weeks | 
| Modified Medical Research Council Dyspnea Scale |  | 6 weeks | 
| COPD Assessment Test |  | 6 weeks | 
| Spirometry |  | 6 weeks |
Reveal LINQ™ Evaluation of Fluid

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the use of subcutaneous impedance measured with an implanted Medtronic Reveal LINQ™ insertable cardiac monitor for use as a fluid status monitor in hemodialysis patients. The study will measure the changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions. Subcutaneous impedance trends will also be evaluated between dialysis sessions.

Official Title
-----------------
Reveal LINQ™ Evaluation of Fluid

Conditions
-----------------
End Stage Renal Disease

Intervention / Treatment
-----------------
* Device: Reveal LINQ™ Insertable Cardiac Monitor


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who currently undergo in-clinic hemodialysis treatment prescribed 2 or 3 times per week Patients willing to be implanted with the Reveal LINQ™ device Patients greater than 21 years of age Patients willing and able to comply with the study procedures including giving informed consent Exclusion Criteria: Patient has an active implanted cardiac medical device (e.g. IPG, ICD, CRT, etc) Patients who currently undergo home dialysis treatment Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from a Medtronic study manager. Patient with a recent infection defined as 1) bacteremia within 60 days OR 2) (nonbacteremic) infection within 14 days Patient not suitable for Reveal LINQ™ implantation (e.g., severe cachexia, dermatologic conditions of the skin, or major medical or social conditions expected to reduce survival to < 6 months), in the opinion of the investigator

Ages Eligible for Study
-----------------
Minimum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Diagnostic<br>'Reveal LINQ™ Insertable Cardiac Monitor' will be used to measure changes in subject subcutaneous impedance and compare with the fluid status assessed by the volume removed from the hemodialysis subject during dialysis sessions. | Device: Reveal LINQ™ Insertable Cardiac Monitor<br>* Insertable cardiac monitor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Average Fluid Volume Removed | The average fluid volume removal during the dialysis session over all patients. | 24 Days | 
| Change in Subcutaneous Impedance | The change in impedance from the beginning to the end of a dialysis session, averaged over all patients and dialysis sessions | 24 days |
A Study of RO5028442 in Adult Male High-Functioning Autistic Patients

Study Overview
=================
Brief Summary
-----------------
This multi-center, randomized, double-blind study will evaluate exploratory biomarkers and the safety and tolerability of a single dose of RO5028442 in adult male high-functioning autistic patients. In a cross-over design, patients will be randomized to receive either a single dose of RO5028442 or matching placebo with a washout period of 7-14 days. Anticipated time on study is up to approximately 9 weeks.

Official Title
-----------------
A Multi-centre, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over, Exploratory Biomarker and Safety and Tolerability Study of a Single Dose of RO5028442 in Adult Male High-functioning Autistic Patients

Conditions
-----------------
Autistic Disorder

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: RO5028442


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a diagnosis of Autistic Disorder as defined by DSM-IV, confirmed by the team and supported with the Autistic Diagnostic Observation Schedule (ADOS) Male adults, 18 to 45 years of age IQ > 70 (Wechsler Adult Intelligence Scale-Full scale) Body mass index (BMI) 18 to 35 kg/m2 inclusive Aberrant Behavior Checklist (ABC) - Irritability subscale score </= 13 Exclusion Criteria: Positive urine test for drugs of abuse Alcohol and/or substance abuse/dependence during the last 12 months Positive for hepatitis B, hepatitis C or HIV infection Clinically relevant cardiovascular, renal, hepatic or hematologic disease or disorder Active inflammatory pulmonary disease History of epilepsy/seizure disorder (except for simple febrile seizures) Initiation of new or major change in psychosocial intervention within 4 weeks prior to randomization Treatment with any investigational agent within 90 days prior to screening History of hypersensitivity or allergic reactions

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br> | Drug: RO5028442<br>* Single dose<br>|
| Placebo Comparator: 2<br> | Drug: Placebo<br>* Single dose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficacy: Behavior assessments |  | up to 24 hours post-dose | 
| Safety: Incidence of adverse events |  | up to 24 hours post-dose |
COVID-19 Booster Incentives

Study Overview
=================
Brief Summary
-----------------
The goal of this work is to understand whether small financial incentives and messaging can increase the take-up of COVID-19 boosters among patients empaneled at a county public health system. The motivation for this work is the relatively low take-up of COVID-19 boosters. In California, where our experiment is based, only 59% of the population has been boosted, with only 13% receiving the recommended bivalent booster (State of California, 2022).

Official Title
-----------------
COVID-19 Booster Incentives in a County-Run Health System

Conditions
-----------------
Booster Message, Booster Message + Financial Incentive

Intervention / Treatment
-----------------
* Behavioral: Messaging
* Behavioral: Financial Incentive
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age: 18 and above At least one COVID-19 vaccination (primary series or monovalent booster) but no vaccination dose within the past 2-months. Active phone number or email Exclusion Criteria: 1. Opt-out of health system messaging

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Message Only<br>Email or SMS Booster Vaccination Reminder | Behavioral: Messaging<br>* Booster reminder message<br>|
| Experimental: Message + Financial Incentive<br>Email or SMS Booster Vaccination Reminder + Offer of a financial incentive for getting boosted in the next 2 weeks. | Behavioral: Messaging<br>* Booster reminder message<br>Behavioral: Financial Incentive<br>* Financial Incentive for getting boosted within 2-weeks of the message<br>|
| Placebo Comparator: Control<br>No message or financial incentive | Other: Placebo<br>* Treatment as usual; no additional message and no incentive.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vaccine booster | Received a booster vaccination within 2-weeks of message. | 2 weeks |
Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effect on LH levels of the 5-day CC administration during luteal phase in oocyte donors, to investigate whether the CC corrects the suppressed LH levels in the luteal phase and whether it prolongs the luteal phase in the agonist triggered antagonist cycles.

Official Title
-----------------
Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in Agonist Triggered GnRH Antagonist in Vitro Fertilization Cycles. Phase IV, Single-centre, Open-label, Controlled Clinical Trial.

Conditions
-----------------
Female Infertility

Intervention / Treatment
-----------------
* Drug: Clomifene Citrate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Oocyte donors 18-35 years old BMI 18-29 Kg/m2 Normal basal hormonal levels No contraceptive pill Exclusion Criteria: Polycystic ovarian syndrome (PCOS) Previous participation in the study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 35 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Clomifene Citrate<br>Clomifene Citrate 50 mg | Drug: Clomifene Citrate<br>* Clomiphene citrate 100 mg daily for 5 days<br>|
| No Intervention: Control<br>No intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| LH Levels (IU) |  | Luteal phase (up to 2 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Endometrial development (Noyes criteria) |  | Luteal phase (1 day) |